World Ovarian Cancer Drugs Market - Opportunities and Forecasts, 2020-2027
|
A00273
|
Pages: NA
|
May 2020 |
5558 Views
|
|
|
|
Author(s) :
NA
|
Tables: NA
|
Charts: NA
|
Formats*:
|
|
Ovarian cancer is cancer that affects the ovaries. According to the WHO, an estimated 2,38,700 women were diagnosed with ovarian cancer in 2012. The report analyzes the demand for ovarian cancer drugs, which would contribute to the growth of the market. It focuses on both generic and brand drugs that are used to treat ovarian cancer and their impact on the market.
The market is driven by the increasing incidence of ovarian cancer. The need for more effective treatment options is pushing growth of the market. While the market is dominated by generics such as paclitaxel and carboplatin, it is expected that drugs such as Bevacizumab (Avastin), Pazopanib (Votrient) would boost the growth of this market. Development of drugs with improved efficacy is a challenge for this market. The opportunity for this market lies in developing new drugs for treating ovarian cancer.
Global Ovarian Cancer Drugs Market Analysis by Drug
The drugs used to treat ovarian cancer include Paclitaxel, Cisplatin, Adriamycin PFS (Doxorubicin Hydrochloride), Carboplatin, Cyclophosphamide, Platinol (Cisplatin), Paraplatin (Carboplatin), Doxorubicin Hydrochloride Liposome, Evacet (Doxorubicin Hydrochloride Liposome), Cytoxan (Cyclophosphamide), Paraplat (Carboplatin), Taxol (Paclitaxel), Neosar (Cyclophosphamide), Gemcitabine Hydrochloride, Platinol-AQ (Cisplatin), Topotecan Hydrochloride, Gemzar (Gemcitabine Hydrochloride), Hycamtin (Topotecan Hydrochloride), Doxorubicin Hydrochloride, LipoDox (Doxorubicin Hydrochloride Liposome), Dox-SL (Doxorubicin Hydrochloride Liposome), Clafen (Cyclophosphamide), Adriamycin RDF (Doxorubicin Hydrochloride), DOXIL (Doxorubicin Hydrochloride Liposome) and others. Treatment for ovarian cancer mostly includes a combination of two drugs, usually a platinum compound (Cisplatin or carboplatin) and a taxane (Paclitaxel or docetaxel).
Global Ovarian Cancer Drugs Market Analysis by Geography
The market for ovarian cancer is segmented geographically into North America, Europe, Asia Pacific and LAMEA. North America is the major revenue generating market mainly due to the prevalence of ovarian cancer. According to the American cancer society, an estimated 21,980 women would be diagnosed with ovarian cancer in 2014 in the US. Europe is the second largest market as the incidence for ovarian cancer is high in Europe.
Competitive Analysis
The companies include Roche, Amgen, Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca and others. In Dec 2011, Roche received EU approval for it drug Avastin (bevacizumab) to be used in combination with carboplatin and paclitaxel as treatment for ovarian cancer.
High Level Analysis
Market analysis by porter’s five-force model shows that the bargaining power of the buyer is high in this market as the market is dominated by generic drugs and there are many suppliers producing the drugs. The threat of new entrants is moderate as the drugs for treating ovarian cancer are mainly generic and pharmaceutical companies can easily start producing the drugs. Intensity of rivalry is high in this market as competitors are numerous and the drugs are undifferentiated. Top impacting factors have been given to get a clearer understanding of the market.
KEY BENEFITS
- In-depth analysis of the drugs in the market for treatment of ovarian cancer would help in understanding the capacity for growth in this market
- Segmentation by geography would help in identifying the demand for ovarian drugs in each region
- Key drivers and opportunities would help in a deeper understanding of the scope of the market
- Porter’s five-force model would give a clear picture of the market and help in making business decisions
- Estimations have been given for the period from 2013 to 2020, which would help in identifying the potential of the market
KEY DELIVERABLES
The ovarian cancer drug market is segmented by drugs and geography.
BY DRUG
- Paclitaxel
- Cisplatin
- Adriamycin PFS (Doxorubicin Hydrochloride)
- Carboplatin
- Cyclophosphamide
- Platinol (Cisplatin)
- Paraplatin (Carboplatin)
- Doxorubicin Hydrochloride Liposome
- Evacet (Doxorubicin Hydrochloride Liposome)
- Cytoxan (Cyclophosphamide)
- Paraplat (Carboplatin)
- Taxol (Paclitaxel)
- Neosar (Cyclophosphamide)
- Gemcitabine Hydrochloride
- Platinol-AQ (Cisplatin)
- Topotecan Hydrochloride
- Gemzar (Gemcitabine Hydrochloride)
- Hycamtin (Topotecan Hydrochloride)
- Doxorubicin Hydrochloride
- LipoDox (Doxorubicin Hydrochloride Liposome)
- Dox-SL (Doxorubicin Hydrochloride Liposome)
- Clafen (Cyclophosphamide)
- Adriamycin RDF (Doxorubicin Hydrochloride)
- DOXIL (Doxorubicin Hydrochloride Liposome)
BY GEOGRAPHY
- North America
- Europe
- Asia Pacific
- LAMEA
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. TOP PLAYER POSITIONING/MARKET SHARE ANALYSIS, 2016
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. PATENT ANALYSIS
CHAPTER 4 OVARIAN CANCER DRUGS MARKET, BY MODALITY
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. CHEMOTHERAPY
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. TARGETED THERAPY
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. HORMONAL THERAPY
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
CHAPTER 5 OVARIAN CANCER DRUGS MARKET, BY DRUGS
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. CARBOPLATIN
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. AVASTIN
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. DOXIL
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. YONDELIS
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. LYNPARZA
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
5.7. OTHER DRUGS
5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by country
CHAPTER 6 OVARIAN CANCER DRUGS MARKET, BY REGION
6.1. OVERVIEW
6.2. NORTH AMERICA
6.2.1. Key market trends, growth factors and opportunities
6.2.2. North America ovarian cancer drugs market, by country
6.2.2.1. U.S. ovarian cancer drugs market
6.2.2.1.1. U.S. market, by modality
6.2.2.1.2. U.S. market, by drugs
6.2.2.2. Canada ovarian cancer drugs market
6.2.2.2.1. Canada market, by modality
6.2.2.2.2. Canada market, by drugs
6.2.2.3. Mexico ovarian cancer drugs market
6.2.2.3.1. Mexico market, by modality
6.2.2.3.2. Mexico market, by drugs
6.2.3. North America ovarian cancer drugs market, by modality
6.2.4. North America ovarian cancer drugs market, by drugs
6.3. EUROPE
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Europe ovarian cancer drugs market, by country
6.3.2.1. Germany ovarian cancer drugs market
6.3.2.1.1. Germany market, by modality
6.3.2.1.2. Germany market, by drugs
6.3.2.2. France ovarian cancer drugs market
6.3.2.2.1. France market, by modality
6.3.2.2.2. France market, by drugs
6.3.2.3. UK ovarian cancer drugs market
6.3.2.3.1. UK market, by modality
6.3.2.3.2. UK market, by drugs
6.3.2.4. Italy ovarian cancer drugs market
6.3.2.4.1. Italy market, by modality
6.3.2.4.2. Italy market, by drugs
6.3.2.5. Spain ovarian cancer drugs market
6.3.2.5.1. Spain market, by modality
6.3.2.5.2. Spain market, by drugs
6.3.2.6. Rest of Europe ovarian cancer drugs market
6.3.2.6.1. Rest of Europe market, by modality
6.3.2.6.2. Rest of Europe market, by drugs
6.3.3. Europe ovarian cancer drugs market, by modality
6.3.4. Europe ovarian cancer drugs market, by drugs
6.4. ASIA-PACIFIC
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Asia-Pacific ovarian cancer drugs market, by country
6.4.2.1. Japan ovarian cancer drugs market
6.4.2.1.1. Japan market, by modality
6.4.2.1.2. Japan market, by drugs
6.4.2.2. China ovarian cancer drugs market
6.4.2.2.1. China market, by modality
6.4.2.2.2. China market, by drugs
6.4.2.3. Australia ovarian cancer drugs market
6.4.2.3.1. Australia market, by modality
6.4.2.3.2. Australia market, by drugs
6.4.2.4. India ovarian cancer drugs market
6.4.2.4.1. India market, by modality
6.4.2.4.2. India market, by drugs
6.4.2.5. South Korea ovarian cancer drugs market
6.4.2.5.1. South Korea market, by modality
6.4.2.5.2. South Korea market, by drugs
6.4.2.6. Rest of Asia-Pacific ovarian cancer drugs market
6.4.2.6.1. Rest of Asia-Pacific market, by modality
6.4.2.6.2. Rest of Asia-Pacific market, by drugs
6.4.3. Asia-Pacific ovarian cancer drugs market, by modality
6.4.4. Asia-Pacific ovarian cancer drugs market, by drugs
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. LAMEA ovarian cancer drugs market, by country
6.5.2.1. Brazil ovarian cancer drugs market
6.5.2.1.1. Brazil market, by modality
6.5.2.1.2. Brazil market, by drugs
6.5.2.2. Saudi Arabia ovarian cancer drugs market
6.5.2.2.1. Saudi Arabia market, by modality
6.5.2.2.2. Saudi Arabia market, by drugs
6.5.2.3. South Africa ovarian cancer drugs market
6.5.2.3.1. South Africa market, by modality
6.5.2.3.2. South Africa market, by drugs
6.5.2.4. Rest of LAMEA ovarian cancer drugs market
6.5.2.4.1. Rest of LAMEA market, by modality
6.5.2.4.2. Rest of LAMEA market, by drugs
6.5.3. LAMEA ovarian cancer drugs market, by modality
6.5.4. LAMEA ovarian cancer drugs market, by drugs
CHAPTER 7 COMPANY PROFILES
7.1. AMGEN
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. ASTRAZENECA
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. BOEHRINGER INGELHEIM
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. CLOVIS ONCOLOGY
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. GLAXOSMITHKLINE PLC
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. JOHNSON & JOHNSON
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. MERCK
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. ROCHE
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. TESARO, INC.
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. ZELTIA
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments
We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:
- Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
- Technologically sophisticated and reliable insights through well audited and veracious research methodology
- Sovereign research proceeds that present a tangible depiction of marketplace
With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.
Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, web-casts and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast
Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develops analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth and forecasts
Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:
- Chief executives and VPs of leading corporations specific to industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)
Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
REQUEST TOC/SAMPLE
Purchase Full Report of
World Ovarian Cancer Drugs Market-
Opportunities and Forecasts, 2020-2027
- Online Only
-
$3,456$3,110 - Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
-
$3,840$3,456 - Restricted to one authorized user
- One print only
- Available in
Excel - Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
-
$5,370$4,833 - Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
-
$6,450$5,805 - Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF -
$8,995$8,096 - Unlimited
within
company/enterprise - Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Library Membership
- $0.00
- Published Content
E-access - Company Profiles
E-access - Newly Added Content Access
- 10 PDF
Downloads - 5 Excel Data
Pack Downloads - 250 Company Profiles PDF Downloads
-
Start reading.
Buy Now
This title and over 12,000+ are available on the Avenue Library. Subscription @ $699 T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.